Trial Profile
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Trametinib (Primary) ; Doxorubicin liposomal; Letrozole; Paclitaxel; Tamoxifen; Topotecan
- Indications Carcinoma; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms LOGS
- 12 Oct 2023 Planned End Date changed from 11 Oct 2023 to 11 Oct 2024.
- 11 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Apr 2018 Planned primary completion date changed from 28 Feb 2018 to 1 Feb 2019.